Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study by P. Dongiovanni et al.
RESEARCH ARTICLE Open Access
Lack of association between peroxisome
proliferator-activated receptors alpha and
gamma2 polymorphisms and progressive liver
damage in patients with non-alcoholic fatty liver
disease: a case control study
Paola Dongiovanni1, Raffaela Rametta1, Anna Ludovica Fracanzani1, Luca Benedan1, Vittorio Borroni1,
Paolo Maggioni1, Marco Maggioni2, Silvia Fargion1, Luca Valenti1*
Abstract
Background: Peroxisome proliferator-activated receptors (PPARs) play key roles in the pathogenesis of
nonalcoholic fatty liver disease (NAFLD).
Aim: to assess the effect of functional single nucleotide polymorphisms (SNPs) of PPARa and PPARg2, previously
associated with insulin resistance and dyslipidemia, on liver damage in NAFLD, whose progression is influenced by
metabolic abnormalities and inherited factors.
Methods: The Leu162Val PPARa and Pro12Ala PPARg2 SNPs were evaluated by restriction analysis. We considered
202 Italian patients with biopsy-proven NAFLD.
Results: The frequency of the evaluated SNPs did not differ between patients and 346 healthy controls. The
presence of the PPARa 162Val allele (prevalence 57%), but not of the PPARg2 12Ala allele (prevalence 18%), was
associated with higher insulin resistance (HOMA-IR index 4.71 ± 3.8 vs. 3.58 ± 2.7, p = 0.026), but not with
hyperglycemia. The PPARa 162Val and PPARg2 12Ala alleles were not associated with the severity of steatosis,
necroinflammation, or fibrosis.
Conclusions: The presence of the PPARa 162Val allele was associated with insulin resistance, but not with liver
damage in NAFLD. Because of the limited power of the present sample, larger studies are needed to exclude a
minor effect of the PPARg2 12Ala allele on necroinflammation/fibrosis in NAFLD.
Background
Nonalcoholic fatty liver disease (NAFLD), affecting 20-
34% of the US and European populations [1,2], is con-
sidered the hepatic manifestation of the metabolic syn-
drome. NAFLD is characterized by hepatic insulin
resistance [3], dyslipidemia [4], and is associated with
increased mortality due to cardiovascular and liver dis-
eases [5,6].
Liver damage progression occurs when fatty liver is
complicated by steatohepatitis (NASH) [5,7,8], which is
thought to be provoked by peripheral insulin resistance
leading to an increased supply of free fatty acids (FFAs)
to the liver, and resulting in oxidative, endoplasmic reti-
culum and cytokine mediated stress [9].
Inherited factors play a major role in the susceptibility
to NAFLD. Indeed, 1) predisposition to NASH appears
to cluster with that for metabolic risk factors within
families, 2) ethnic differences, partially explained by a
different prevalence of patatin-like phospholipase
domain-contain 3 protein (PNPLA3) variants, have been
reported [10-12], and 3) studies in twins demonstrated a
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high heritability of liver enzymes values reflecting liver
fat content [13]. In addition, single nucleotide poly-
morphisms (SNPs) in genes involved in inflammation,
oxidative stress, and fibrogenesis have been associated
with the severity of NAFLD [14-19], and recently it has
been demonstrated that SNPs influencing Insulin recep-
tor activity predispose to liver damage in NAFLD, con-
firming that insulin resistance has a causative role in the
progression of liver disease [20].
Peroxisome proliferator-activated receptor-alpha
(PPARa) is a member of the nuclear hormone receptor
superfamily, molecular target of long chain fatty acids,
eicosanoids and fibrates (22), and it is expressed at high
levels in tissues that catabolize fatty acids such as the
liver, skeletal muscles, and the heart. PPARa agonists
lower plasma lipid levels, decrease intrahepatic and mus-
cle lipid accumulation, normalize glucose and insulin
levels, and reduce the risk of type 2 diabetes in rodent
models [21-23]. It has been reported that PPARa down-
regulation is involved in NASH pathogenesis by redu-
cing FFAs catabolism [24]. Furthermore, the PPARa
agonists gemfibrozil and fenofibrate improve dyslipide-
mia and insulin sensitivity in humans [25]. Preliminary
results indicate that another SNP in the PPARa gene,
the Val227Ala substitution, may also been implicated in
the pathogenesis of NAFLD and could play a protective
role against the development of obesity [26]. Since
increased hepatic fat, the pathological hallmark of
NAFLD, negatively influences insulin signaling [27] and
is associated with activation of fibrogenesis [28], we
hypothesized that the Leu162Val variant of PPARa, pre-
viously associated with decreased hepatic lipolysis, dysli-
pidemia and type 2 diabetes (table 1), could influence
liver damage in NAFLD [29].
Peroxisome proliferator-activated receptor-gamma
(PPARg), the molecular target of glitazones, is mainly
known to regulate adipocytes differentiation and FFAs
uptake and storage, and the PPARg2 isoform is highly
expressed in adipose tissue. PPARg activation promotes
adipogenesis, fatty-acid storage, and eventually obesity,
insulin resistance, and type 2 diabetes. Pharmacological
activation of PPARg ameliorates insulin resistance in
diabetes, and has been reported to decrease liver
damage in NAFLD by restoring adipose tissue insulin
sensitivity, thus decreasing FFAs flux to the liver [30,31].
The Pro12Ala SNP of PPARg2, which has been suggest
to induce a modest impairment of transcriptional activa-
tion due to decreased DNA-binding affinity (table 1),
was associated with decreased PPARg activity in adipose
tissue, and decreased insulin resistance and diabetes in
Caucasians [32]. However, the effect of the Pro12Ala
polymorphism on the risk of diabetes is still controver-
sial [33]. As pharmacological modulation of PPARg
showed promising results on steatosis and necroinflam-
mation in most, but not all, patients with NAFLD,
whereas the effect on fibrosis is still undefined [30,34],
we hypothesized that functional genetic variants may
influence disease progression. In addition, the evaluation
of the effect of inherited variability of PPARg2 on liver
damage progression may shed light on the possible
long-term effects of treatment with PPARg agonists on
liver fibrosis in NAFLD.
Aim of this study was to assess the effect of these
well-characterized common functional PPARa Leu162-
Val and PPARg2 Pro12Ala SNPs on the severity of liver
disease in a series of Italian patients with biopsy proven
NAFLD.
Methods
Subjects
Informed written consent was obtained from each
patient and control subject, and the study conforms to
the ethical guidelines of the declaration of Helsinki.
Two hundred two consecutive Italian unrelated
patients from Northern Italy with histologically proven
NAFLD and available DNA samples, diagnosed between
January 1999 and January 2007 were included. Other
causes of liver disease were excluded, including
increased alcohol intake (> 30/20 g/day for M/F) [35], as
confirmed by at least one family member and carboxy-
desialylated transferrin determination, HBV and HCV
chronic viral hepatitis, autoimmune hepatitis, hereditary
hemochromatosis, a1-antitrypsin deficiency, Wilson’s
disease, and drug induced liver disease. Metabolic para-
meters and fasting insulin levels, as determined by RIA,
were available for each patient. Demographic and clini-
cal features available are shown in table 2.
The control group included 346 Italian subjects out of
a larger series of 482 blood donors (71%) of the same
geographical origin of patients without clinical and bio-
chemical evidence of liver and metabolic disease and no
alcohol abuse. We excluded subjects with ALT > 30/18
IU/ml in males/females [36], GGT > 35 IU/ml, BMI >
28, abdominal circumference > 100 cm, glucose levels ≥
100 mg/dl, triglycerides ≥ 150 mg/dl, or a fatty liver
Table 1 Metabolic pathways regulated by the considered
genes, effect of polymorphisms on protein function and
metabolic parameters.
Gene Function Polymorphism Effect Previous
association
PPARa Induces lipolysis Lys162Val
(rs1800206)
- Insulin
resistance
Dyslipidemia
Diabetes [29]
PPARg2 Induces lipogenesis in
adipose tissue
Pro12Ala
(rs1801282)
- Insulin
sensitivity
[32,40]
-: loss-of-function allele
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index > 35, which has high specificity to rule out
NAFLD in the general population [37]. Fasting insulin
levels were available for 259 subjects.
Histological assessment
Tissue sections were stained with hematoxylin and
eosin, impregnated with silver for reticulin framework,
and stained with Periodic Acid-Schiff (PAS) for glyco-
gen, Periodic Acid-Schiff diastase (DiPAS) for nonglyco-
gen proteins, Perls for iron, and trichrome for collagen.
A single expert pathologist unaware of clinical and
genetic data reviewed biopsies. The presence and sever-
ity of NASH was assessed according to Kleiner et al.
[38]. Briefly, histological activity (NAS: NAFLD activity
score) is graded based on steatosis (0-3), lobular inflam-
mation (0-3), and hepatocyte ballooning (0-2), whereas
liver fibrosis is staged from 0 (absent) to 4 (cirrhosis).
The minimum biopsy size was 1.7 cm and the number
of portal areas 10.
We chose as main outcome a fibrosis cut-off of stage
> 1 according to Kleiner et al. [38], in the attempt to
identify patients with potentially progressive disease at
an early stage [39].
Genetic analysis
DNA was extracted from peripheral blood by the phe-
nol-chloroform method. Success rate in extracting DNA
was 100% for each study group. PPARa Leu162Val
(rs1800206) and PPARg2 Pro12Ala (rs1805192) SNPs
were determined by restriction analysis, as previously
described [29,40] by personnel unaware of the subjects’
clinical status. Moreover, the presence of specific poly-
morphic alleles as detected by restriction analysis was
confirmed in each case by sequencing of random
samples of patients. Samples from both NAFLD patients
and controls have been included in each batch analyzed,
and quality controls were performed to verify the repro-
ducibility of the results. Valid genotypic data were
obtained for > 99% of subjects analyzed. Subjects for
whom incomplete clinical or genetic data were available
were excluded from the analyses.
Statistical analysis
The sample size was calculated on the basis of the
expected relative risk of the presence of a minor allele
versus the wild-type allele, the desired power, and signif-
icance (p < 0.05, two-tailed).
The sample size had a 99% and 75% power of detect-
ing an OR of 1.5 for NAFLD for the presence of the
PPARa Leu162Val (rs1800206) and PPARg2 Pro12Ala
(rs1805192) SNPs, respectively, and a 100% and 83%
power of detecting an OR of 2.0 for fibrosis > 1 in
patients with NAFLD, according to the observed geno-
type frequencies and liver damage distribution, for the
presence of the PPARa Leu162Val (rs1800206) and
PPARg2 Pro12Ala (rs1805192) SNPs, respectively (76%
and 33% power of detecting an OR of 1.5). Results are
expressed as means ± standard deviation and considered
significant when p < 0.05 (two-tailed). Mean values were
compared by t-test and by Wilcoxon test, as required.
Frequencies were compared by Fisher’s exact test.
To allow comparisons with the previous literature and
due to the relatively low frequency of the minor alleles
evaluated, the effect of genetic factors was tested under
the assumption of a dominant effect. Analyses were car-
ried out with JMP 6.0 statistical analysis software (SAS
Institute Inc, Cary, NC).
Results
Clinical and genetic features of patients with NAFLD and
controls
Despite similar age and sex distribution, as expected by
enrolment criteria, patients with NAFLD had higher
BMI, total cholesterol and triglycerides, lower HDL cho-
lesterol, and higher insulin and HOMA-R index, ALT
and GGT levels than controls (table 2).
The frequency distributions of the evaluated SNPs
were not significantly different between Italian patients
with NAFLD and controls (table 3). The genotype distri-
bution of the polymorphic alleles was in Hardy-Wein-
berg equilibrium both in patients and controls.
Effect of genetic factors on insulin resistance and
metabolic features
The effect of inherited factors on insulin resistance,
evaluated by HOMA-R index, the presence of diabetes/
IFG, and HDL levels is shown in table 4. The PPARa
162Val allele was nearly associated with higher HDL
Table 2 Demographic and clinical features of patients
with NAFLD and controls.
Italian controls Italian adult NAFLD
number 346 202
Sex F 74 (21) 41 (20)
Age years 47.7 ± 12 47.4 ± 11
BMI Kg/m2 25.1 ± 2.6* 27.4 ± 3.8*
Total cholesterol mg/dl 194 ± 34* 211 ± 43*
HDL cholesterol mg/dl 56.2 ± 13* 45.1 ± 12*
Triglycerides mg/dl 89 ± 43* 158 ± 91*
Fasting insulin IU/ml 13.4 ± 7* 16.8 ± 11*
Glucose mg/dl 88.5 ± 10* 98 ± 24*
HOMA-IR 2.9 ± 1.6* 4.1 ± 3.3*
ALT UI/ml 23 ± 9* 65 ± 46*
GGT UI/ml 23 ± 16* 87 ± 96*
Fibrosis stage F0/F1/F2/F3/F4 - 104/61/23/8/6
(52/30/11/4/3)
* p < 0.0001 between Italian patients and controls, ():% values
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levels at univariate (46.1 ± 14 vs. 43 ± 10 mg/dl, p =
0.051), but not at multivariate analysis, and patients
positive for this allele had a trend for a higher preva-
lence of diabetes/IFG compared to those without (25%
vs. 16%; p = 0.06). No significant effect on HDL levels
and diabetes/IFG was observed for the PPARg2 12Ala
allele.
In patients with NAFLD, the PPARa 162Val allele was
significantly associated with higher HOMA-R (4.71 ±
3.8 vs. 3.58 ± 2.7, p = 0.026), and the association per-
sisted after the exclusion of 9 diabetic patients treated
with metformin (4.8 ± 3.8 vs. 3.6 ± 2.6; p = 0.04). We
did not found any association between HOMA-R and
the PPARa SNP in controls subjects. In contrast, the
PPARg2 12Ala allele had no effect on insulin resistance
(Figure 1). The evaluated SNPs were not significantly
associated with age, sex, BMI, the presence of hyperten-
sion, serum triglycerides, ALT, GGT, and ferritin levels,
both in patients and in controls.
Effect of genetic factors on liver disease severity
The effect of inherited factors on the severity of liver
disease, evaluated as presence of severe histological
activity (NAS > 5) and of severe fibrosis (Kleiner > 1), is
shown in figure 2 and 3 respectively. No significant
effect of the PPARa 162Val and PPARg2 12Ala alleles
was observed on liver damage. The prevalence of NAS >
5 was similar between patients positive and negative for
the PPARa 162Val allele (6% vs. 8%; p = ns). In patients
positive for the PPARg2 12Ala allele, the prevalence of
NAS > 5 was lower compared to that observed in nega-
tive patients (3% vs. 8%; p = ns). Although the PPARg2
12Ala allele was associated with a lower prevalence of
severe histological activity, the sample size is too small
to cross the statistical significance threshold. The preva-
lence of fibrosis > 1 was 22% in patients positive for
PPARa 162Val and 14% in those negative for this allele
(p = ns). Also for the PPARg2 SNP, the prevalence of
fibrosis > 1 was similar in patients carrying the 12Ala
allele compared to the negative ones (19% vs. 18%; p =
ns).
Table 3 Frequency distribution of evaluated gene
polymorphisms in 202 Italian patients with NAFLD and
346 controls.
Gene Genotype Controls Patients P
PPARa
(rs1800206)
Lys162Lys 137 (40%) 87 (43%) ns
Lys162Val 159 (46%) 93 (46%)
Val162Val 50 (14%) 22 (11%)
PPARg2
(rs1805192)
Pro12Pro 295 (85%) 166 (82%) ns
Pro12Ala 50 (14%) 33 (16%)
Ala12Ala 1 (1%) 3 (2%)
P values are shown if < 0.1.
ns: not significant
Table 4 Metabolic parameters of patients with NAFLD
subdivided according to the presence or absence of the
PPARa 162Val and PPARg2 12Ala alleles.
Polymorphic allele
Gene Present Absent p
HDL 46.1 ± 14 43 ± 10 0.051
PPARa Homa-R 4.5 ± 3.7 3.6 ± 2.7 0.026
Diabetes/IGT 40 (25) 19 (16) 0.060
HDL 50.7 ± 14 49.4 ± 14 ns
PPARg2 Homa-R 4.1 ± 2.1 4.1 ± 3.5 ns
Diabetes/IGT 8 (18) 51 (22) ns
P values are shown if < 0.1.
():% values, ns: not significant.
Figure 1 HOMA-R index in 202 patients with non-alcoholic
fatty liver disease (NAFLD) subdivided according to the
presence or absence of the PPARa 162Val and PPARg2 12Ala
SNPs.
Figure 2 Prevalence of severe histological activity (NASH
activity score (NAS) > 5) in 202 biopsied patients with non-
alcoholic fatty liver disease (NAFLD), subdivided according to
the presence or absence of the PPARa 162Val and PPARg2
12Ala SNPs.
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Adjustment for age, BMI, ALT levels and diabetes/
IGT did not modify the lack of association between the
evaluated SNPs and liver damage.
Discussion
In this paper, we evaluated the effect of well-character-
ized, functional, common SNPs of genes involved in the
regulation of lipid metabolism, and which are amenable
of pharmacologic modulation, on the severity of liver
injury in patients with NAFLD. Our results, obtained in
the largest series of well characterized patients with liver
histology available to date, indicate that the PPARa
162Val allele is associated with insulin resistance but
not with liver damage, whereas the PPARg2 12Ala SNP
is neither associated with insulin resistance nor with
liver damage.
Since NAFLD is considered the hepatic expression of
metabolic syndrome, and has a strong genetic compo-
nent [11,12], we reasoned that genetic factors influen-
cing lipid metabolism might predispose to progressive
liver disease in affected subjects [27,29,32]. PPARs,
because of 1) their key role in NAFLD pathogenesis 2)
genetic variability determining altered function 3) are
targets of approved drugs, represent ideal candidate
genes.
We preliminarily compared the distribution of PPARs
SNPs in Italian patients with NAFLD and healthy con-
trols with normal liver enzymes [36] and absence of
metabolic alterations. Even if our sample size had a
good power of detecting a 50% increased risk of NAFLD
for the presence of the evaluated genetic factors, the
prevalence of the SNPs did not differ between patients
and controls, suggesting that they do not represent a
risk factor for NAFLD. However, we cannot exclude
that these genetic variants may influence the risk of
NAFLD in patients carrying acquired risk factors, such
as obesity, or that other rarer and less characterized var-
iants of these genes may be associated with NAFLD
[26].
Indeed, due to the very strict selection criteria our
control subjects had no metabolic risk factors and a low
fatty liver index, but we did not get direct evidence of
the absence of mild fatty liver disease, which may occur
even in absence of the metabolic syndrome and abnor-
mal liver function test. Notwithstanding, the main goal
of this study was to ascertain whether PPARs SNPs
affected the severity of liver disease in patients with
biopsy proven NAFLD.
The 162Val PPARa SNP is a loss-of-function allele
that has been associated with decreased hepatic lipolysis,
dyslipidemia and progression of type 2 diabetes (22).
Results indicated that the 162Val SNP, present in 57%
of the patients, was associated with increased insulin
resistance in patients but not in controls, suggesting a
possible interaction between liver fat and the PPARa
162Val allele in the pathogenesis of insulin resistance.
Indeed, this genetic variant is supposed to increase insu-
lin resistance and liver fat content by reducing PPARa
driven lipolysis, potentially explaining our findings (22).
The biological function of this nuclear receptor may
also account for the lack of association with hepatic
damage despite heightened insulin resistance [41].
Indeed, fatty acid oxidation, contrasted by the 162Val
allele, represents a major source of reactive oxygen spe-
cies that trigger lipoperoxidation in NAFLD [9]. Thus,
in patients with the 162Val allele the risk related to
increased insulin resistance may be balanced by the pro-
tective effect of decreased oxidative stress.
The 12Ala PPARg2 SNP is a loss-of-function allele
that been associated with decreased PPARg activity in
adipose tissue, decreased insulin resistance and diabetes
in Caucasians [32]. The 12Ala allele, present in 18% of
NAFLD patients, was neither associated with liver
damage nor with insulin sensitivity. The lack of associa-
tion between PPARg2 SNP and insulin resistance is pos-
sibly related to a prevalent effect of this gene on insulin
resistance in tissues different from the liver. We cannot
exclude that the evaluated genetic factors may confer a
small increase (less than 1.5-fold and 2-fold for the
PPARa and PPARg2 SNPs, respectively, a threshold for
which we had a very good power to detect an associa-
tion with progressive disease) in the risk of progressive
disease, but a larger sample is required to verify this
hypothesis. However, the possible effect would be much
less strong than that exerted by other genetic variants,
such as those influencing insulin receptor signaling and
the PNPLA3 rs738409 SNP, which were significantly
associated with liver fibrosis in the same series [42,43].
We believe that the high relevance of these two
PPARs genes for the pathogenesis of liver damage in
Figure 3 Prevalence of fibrosis stage > 1 in 202 biopsied
patients with non-alcoholic fatty liver disease (NAFLD),
subdivided according to the presence or absence of the PPARa
162Val and PPARg2 12Ala SNPs.
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NASH, and the clinical, although still investigational and
off-label, use of PPARg agonists to treat NASH, requires
a deeper knowledge of the relationship between these
two genes and NAFLD. Since it is possible that these
SNPs may confer a small increase in the risk of NASH
progression, which could not be detected by the sample
size of this study (this is especially true for the PPARg2
SNP, due to the lower prevalence), we suggest that the
issue could be addressed by meta-analysis of the present
and future reports. In addition, as we are moving
towards individualized medicine, these data could pro-
vide the basis to design pharmacogenetic studies to
address whether the therapeutic efficacy of PPARg ago-
nists in patients NASH is affected by the PPARg2 12Ala
SNP. Noteworthy, the effect of the Pro12Ala SNP on
diabetes risk is still controversial. Indeed, some Authors
have reported that, in contrast to previous reports, the
Ala12 allele protects against the development of diabetes
[44,45], so that the observed trend for a decreased NAS
activity in patients carrying the 12Ala allele may reflect
a reduced risk for progressive liver damage in subjects
carrying this genetic variant, although the difference was
not significant due to the insufficient power of the
study. This interpretation would be consistent with a
protective effect of PPARg agonists on histological activ-
ity, despite the lack of association between the PPARg2
12Ala SNP and insulin resistance in the present series
of patients with NAFLD.
Conclusions
In conclusion, this study indicates that the presence of
the PPARa 162Val and PPARg2 12Ala SNPs influencing
lipid metabolism and insulin sensitivity is not a major
determinant of progressive liver damage in Caucasian
patients with NAFLD. In addition, our data suggest that
insulin resistance does not always translate in fibrosis, in
that patients carrying the PPARa Pro12Ala SNP had
increased insulin resistance without different severity of
liver damage, and that the genetic background underly-
ing metabolic abnormalities has a major role in deter-
mining the clinical outcome [42].
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